{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T23:13:00Z","timestamp":1747177980653,"version":"3.40.5"},"reference-count":14,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia &amp; Lymphoma"],"published-print":{"date-parts":[[2021,5,12]]},"DOI":"10.1080\/10428194.2021.1876869","type":"journal-article","created":{"date-parts":[[2021,1,24]],"date-time":"2021-01-24T10:10:41Z","timestamp":1611483041000},"page":"1510-1513","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Routine use of gemtuzumab ozogamicin in 7\u2009+\u20093-based inductions for all \u2018non-adverse\u2019 risk AML"],"prefix":"10.1080","volume":"62","author":[{"given":"Abdullah","family":"Ladha","sequence":"first","affiliation":[{"name":"Division of Hematology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gavin","family":"Hui","sequence":"additional","affiliation":[{"name":"Department of Medicine, Stanford University, Stanford, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edna","family":"Cheung","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Stanford Health Care, Stanford, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Berube","sequence":"additional","affiliation":[{"name":"Division of Hematology, Stanford Cancer Institute, Stanford University, Stanford, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven E.","family":"Coutre","sequence":"additional","affiliation":[{"name":"Division of Hematology, Stanford Cancer Institute, Stanford University, Stanford, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Gotlib","sequence":"additional","affiliation":[{"name":"Division of Hematology, Stanford Cancer Institute, Stanford University, Stanford, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michaela","family":"Liedtke","sequence":"additional","affiliation":[{"name":"Division of Hematology, Stanford Cancer Institute, Stanford University, Stanford, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6274-0763","authenticated-orcid":false,"given":"Tian Y.","family":"Zhang","sequence":"additional","affiliation":[{"name":"Division of Hematology, Stanford Cancer Institute, Stanford University, Stanford, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori","family":"Muffly","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation, Stanford Cancer Institute, Stanford University, Stanford, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel N.","family":"Mannis","sequence":"additional","affiliation":[{"name":"Division of Hematology, Stanford Cancer Institute, Stanford University, Stanford, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,1,24]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0486"},{"key":"CIT0002","unstructured":"Food and Drug Administration. Gemtuzumab approval letter; 2000, May 17. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2000\/21174_MYLOTARG_APPROV.PDF."},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-466706"},{"key":"CIT0004","unstructured":"Food and Drug Administration. FDA approves Gemtuzumab Ozogamicin for CD33 positive AML; 2017, September 1. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-gemtuzumab-ozogamicin-cd33-positive-AML."},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60485-1"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.244"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23795"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70281-5"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01406"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0806-0"},{"key":"CIT0011","unstructured":"National Comprehensive Cancer Network Clinical Practice Guideline on Acute Myeloid Leukemia Version 1.2021; 2020, October 14. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/aml.pdf."},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.188888"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25854"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004583"}],"container-title":["Leukemia &amp; Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2021.1876869","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T04:24:08Z","timestamp":1646972648000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2021.1876869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,24]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,5,12]]}},"alternative-id":["10.1080\/10428194.2021.1876869"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2021.1876869","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"type":"print","value":"1042-8194"},{"type":"electronic","value":"1029-2403"}],"subject":[],"published":{"date-parts":[[2021,1,24]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-11-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}